The Bispecific Antibodies For Cancer Market is being driven by Increasing prevalence of cancer
The Bispecific Antibodies For Cancer Market is expected to grow at a CAGR of 6.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 338 million. Bispecific antibodies represent a burgeoning cancer immunotherapy segment, offering potential benefits in oncology treatments. Companies like Aptevo Therapeutics and Xencor are collaborating with industry giants such as Roche and Amgen to commercialize these innovative therapies. Amgen's BiTEs platform and MicroGenics' DART antibody platform have been instrumental in the development of bispecific antibodies. Genentech, a Roche subsidiary, has introduced CrossMAb technology, enabling bispecific antibodies to bind selectively via their light and heavy chains, ensuring only intended interactions occur in the antibody's short arm.
Get more information on Bispecific Antibodies For Cancer Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
233 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.9% |
|
Market growth 2025-2029 |
USD 338 million |
|
Market structure |
fragmentation |
|
YoY growth 2024-2025(%) |
6.4 |
|
Key countries |
US, Ireland, Canada, India, China, Hungary, Germany, Japan, UK, and Brazil |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Bispecific Antibodies for Cancer market utilizes fusion protein technology to create immunotherapies with antigen specificity. Epitope mapping is crucial for target identification, while preclinical development involves cell line screening, in vitro assays, and animal models. Tumor heterogeneity necessitates toxicology studies and combination therapies. Molecular profiling through gene expression analysis, pathway analysis, and protein engineering aid in understanding cancer mechanisms. Glycosylation patterns, half-life extension, formulation development, serum stability, and treatment response are essential for optimization. Quality by design, process validation, analytical methods, regulatory compliance, and clinical development plans ensure safety and efficacy. Drug metabolism and adverse events are critical considerations throughout development.
In the dynamic landscape of the global biotechnology industry, the bispecific antibodies market for cancer therapy represents a significant growth opportunity. This segment of the market encompasses companies and research organizations specializing in antibody engineering, targeted cancer therapy, immunoconjugate design, and the production of bispecific antibody formats. According to market research firm Technavio, the global healthcare market, which includes the revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, is poised for expansion. Key growth drivers include the increasing global population aging, with Europe and North America projected to have over 25% of their populations reaching 60 years or above by 2030 and 2050, respectively. This demographic shift will fuel the demand for advanced healthcare solutions, including bispecific antibodies for cancer therapy.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
